A clinical trial site receives an urgent safety communication from the sponsor indicating that a new risk of liver toxicity has been identified. What is the investigator's IMMEDIATE obligation?
-
A
Discontinue all enrolled participants from the study
-
B
Review the communication, notify the IRB, and assess currently enrolled participants per sponsor guidance
-
C
Wait for FDA confirmation before taking any action
-
D
Inform participants only at their next scheduled visit